ATPC - Rasio utang marang kapitalisasi buku agapeatpgroup.com

Logo grafis Agape ATP (ATPC)

The debt-to-equity ratio history demonstrates the financial stability of Agape ATP Corporation (ATPC), with 0.00 serving as the current value of this metric. Efficient omnichannel delivery in Asia optimizes logistics costs for supplements. However, currency fluctuations and regulatory oversight of sales create certain risks. Stable customer loyalty to wellness programs confirms the brand's high reputation.

ATPC (Agape ATP) riwayat Utang marang nilai buku saka 21.02.2024 nganti 28.10.2026
Barang utama Agape ATP

Investors are assessing the resilience of Agape ATP Corporation (ATPC) through the lens of debt-to-equity leverage. As management adapts to new regulatory standards, stabilizing cash flows becomes critically important. The debt-to-capitalization ratio reflects the proportion of liabilities relative to the business's net assets. A decrease in this metric minimizes default risk, while an increase signals aggressive borrowing. This metric allows analysts to filter out market noise and determine the issuer's actual financial cushion.

Pesaing Agape ATP Corporation (ATPC)

Utang-utang marang kapitalisasi buku ASND (Ascendis Pharma A/S)|madrigalpharma.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Corcept Therapeutics Incorporated (CORT)|RYTM: Rasio utang marang aset resik|AKRO (Akero Therapeutics Inc) - Rasio utang marang kapitalisasi buku|Metsera Therapeutics (MTSR) - Utang marang nilai buku|MLTX (MoonLake Immunotherapeutics) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Utang marang nilai buku|Rasio utang marang aset resik SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Rasio utang marang kapitalisasi buku|Utang marang nilai buku 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Utang-utang marang kapitalisasi buku|structuretx.com (GPCR) - Utang-utang marang nilai buku|MDXG - Utang marang nilai buku|Rezolute Inc (RZLT) - Utang marang modal buku|LXRX (Lexicon Pharma) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku MBX Corp|Utang-utang marang kapitalisasi buku Altimmune, Inc. (ALT)|Rasio utang marang kapitalisasi buku AARD (aardvarktherapeutics.com)|SGMT: Rasio utang marang kapitalisasi buku|BioAge Labs - Utang-utang marang nilai buku|BMEA - Rasio utang marang kapitalisasi buku|QNCX - Rasio utang marang kapitalisasi buku|Fractyl Health, Inc. - Utang-utang marang kapitalisasi buku|VTVT (vTv Therapeutics) - Utang-utang marang aset resik|PLUR: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik SYBX|Rasio utang marang kapitalisasi buku LPCN (Lipocine Corp)|Utang marang nilai buku matinasbiopharma.com (MTNB)|Utang-utang marang kapitalisasi buku SPRB (Spruce Biosciences, Inc.)|Utang-utang marang kapitalisasi buku galecto.com GLTO|Utang-utang marang kapitalisasi buku CTCX|LUMO - Utang marang aset resik|ONVO: Utang-utang marang kapitalisasi buku|RDUS (Radius Pharmaceuticals) - Utang-utang marang kapitalisasi buku